Unichem Laboratories Ltd. - Research Center
506690 UNICHEMLAB Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 14.08 | 14.08 | 14.08 | 14.08 | 14.08 |
| Share application money | 3.06 | 12.05 | 10.68 | 7.75 | 4.83 |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 2,277.48 | 2,358.14 | 2,647.28 | 2,675.50 | 2,628.28 |
| Loan funds | |||||
| Secured loans | 63.89 | 101.68 | 126.10 | - | 15.21 |
| Unsecured loans | - | - | - | - | - |
| Total | 2,358.51 | 2,485.95 | 2,798.14 | 2,697.33 | 2,662.40 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 1,712.11 | 1,684.68 | 1,319.33 | 1,128.74 | 1,039.87 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 547.17 | 448.74 | 356.21 | 278.97 | 211.33 |
| Net block | 1,164.94 | 1,235.94 | 963.12 | 849.76 | 828.53 |
| Capital work-in-progress | 122.36 | 147.82 | 494.18 | 567.73 | 330.84 |
| Investments | 44.07 | 40.51 | 389.80 | 520.42 | 668.28 |
| Net current assets | |||||
| Current assets, loans & advances | 1,532.32 | 1,461.86 | 1,274.99 | 1,181.14 | 1,197.49 |
| Less : current liabilities & provisions | 505.19 | 400.19 | 323.94 | 421.72 | 362.74 |
| Total net current assets | 1,027.14 | 1,061.67 | 951.05 | 759.42 | 834.75 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 2,358.51 | 2,485.95 | 2,798.14 | 2,697.33 | 2,662.40 |
| Notes: | |||||
| Book value of unquoted investments | 42.73 | 39.12 | 125.95 | 283.84 | 249.14 |
| Market value of quoted investments | 1.34 | 1.39 | 263.84 | 236.58 | 419.14 |
| Contingent liabilities | 105.21 | 248.21 | 294.41 | 311.26 | 521.58 |
| Number of equity sharesoutstanding (Lacs) | 704.06 | 704.06 | 704.06 | 704.06 | 704.06 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis